Ten Years of Experience in Treating Patients With Digoxin Toxicity Without Using Digoxin Fab Antibody Treating patients with digoxin toxicity without the use of Digoxin Fab antibodies
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 11 No. 1 (2021),
23 January 2021
Background: Digoxin is extensively prescribed for cardiac diseases, so its chronic or acute toxicity commonly occur. Although digoxin specific antibodies (anti-digoxin Fab) are recommended to be used in patients with cardiac symptoms of digoxin toxicity, there is ongoing controversy about the effectiveness and dose of anti-digoxin Fab. Because our department lacks access to anti-digoxin Fab and the high cost of the antidote, we evaluated 10 years of experience in treating patients with digoxin toxicity without using digoxin Fab antibodies considering outcomes.
Methods: A retrospective study was performed in Khorshid Hospital, affiliated with Isfahan University of Medical Sciences, from October 2008 to September 2018. Patients with acute or chronic digoxin toxicity were included in the study. The patients’ data were gathered and analyzed according to their medical documents.
Results: Out of 150 cases with digoxin toxicity, 38% (n=57) were acute and 62% (n=93) were chronic. About 64.7% (n=97) were female. The most common non-cardiac manifestations of toxicity were gastrointestinal (67.3%, n=101) and neurological symptoms (52.7%, n=79). Bradyarrhythmia (80.5%, n=33) was the most cardiac manifestation in patients with acute (15.8% n=9) and chronic (25.8%, n=24) toxicity. A total of 144 (96%) cases fully recovered with supportive care, and 6 patients (4%) died. None of the cases received anti-digoxin Fab.
Conclusion: The majority of presentations with acute or chronic toxicity recovered with supportive measures without using anti-digoxin Fab.
- Toxicity, Poisoning, Digoxin, Digoxin Antibodies Fab Fragments, Supportive Care
How to Cite
Steiner JF, Robbins LJ, Hammermeister KE, Roth SC, Hammond WS. Incidence of digoxin toxicity in outpatients. The West J Med. 1994; 161(5):474-8. [PMCID] [PMID]
Pincus M. Management of digoxin toxicity. Aust Prescr. 2016; 39(1):18-20. [DOI:10.18773/austprescr.2016.006] [PMID] [PMCID]
Bateman DN. Digoxin-specific antibody fragments: How much and when? Toxicol Rev. 2004; 23(3):135-43. [DOI:10.2165/00139709-200423030-00001] [PMID]
Lapostolle F, Borron SW, Verdier C, Arnaud F, Couvreur J, Megarbane B, et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med. 2008; 34(8):1448-53. [DOI:10.1007/s00134-008-1092-x] [PMID]
Kirkpatrick CH. Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. The digibind study advisory panel. Am J Emerg Med. 1991; 9(2 Suppl 1):7-10. [DOI:10.1016/0735-6757(91)90160-L]
Flanagan RJ, Jones AL. Fab antibody fragments: Some applications in clinical toxicology. Drug safety. 2004; 27(14):1115-33. [DOI:10.2165/00002018-200427140-00004] [PMID]
Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014; 52(8):824-36. [DOI:10.3109/15563650.2014.943907] [PMID]
Hull SM, Mackintosh A. Discontinuation of maintenance digoxin therapy in general practice. Lancet (London, England). 1977; 2(8047):1054-5. [DOI:10.1016/S0140-6736(77)91886-4]
Aarnoudse AL, Dieleman JP, Stricker BH. Age-and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf. 2007; 30(5):431-6. [DOI:10.2165/00002018-200730050-00006] [PMID]
Limon G, Ersoy G, Oray NC, Bayram B, Limon O. Retrospective evaluation of patients with elevated digoxin levels at an emergency department. Turk J Emerg Med. 2016; 16(1):17-21. [DOI:10.1016/j.tjem.2015.10.001] [PMID] [PMCID]
Pita-Fernandez S, Lombardia-Cortina M, Orozco-Veltran D, Gil-Guillen V. Clinical manifestations of elderly patients with digitalis intoxication in the emergency department. Arch Gerontol Geriatr. 2011; 53(2):e106-10. [DOI:10.1016/j.archger.2010.07.003] [PMID]
Kirilmaz B, Saygi S, Gungor H, Onsel Turk U, Alioglu E, Akyuz S, et al. Digoxin intoxication: An old enemy in modern era. J Geriatr Cardiol. 2012; 9(3):237-42. [DOI:10.3724/SP.J.1263.2012.01101] [PMID] [PMCID]
Miura T, Kojima R, Sugiura Y, Mizutani M, Takatsu F, Suzuki Y. Effect of aging on the incidence of digoxin toxicity. Ann Pharmacother. 2000; 34(4):427-32. [DOI:10.1345/aph.19103] [PMID]
Santoro F, Ieva R, Ferraretti A, Carpagnano G, Lodispoto M, De Gennaro L, et al. Acute renal failure, digoxin toxicity and brady-arrhythmia as possible triggers in Tako-Tsubo cardiomyopathy. Int J Cardiol. 2013; 165(3):e51-2. [DOI:10.1016/j.ijcard.2012.11.015] [PMID]
Kockova R, Skvaril J, Cernohous M, Maly M, Kocka V, Linhart A. Five year two center retrospective analysis of patients with toxic digoxin serum concentration. Int J Cardiol. 2011; 146(3):447-8. [DOI:10.1016/j.ijcard.2010.10.114] [PMID]
Chan BS, Isbister GK, O’Leary M, Chiew A, Buckley NA. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Clin Toxicol (Phila). 2016; 54(6):488-94. [DOI:10.1080/15563650.2016.1175620] [PMID]
Goldberger ZD, Goldberger AL. Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol. 2012; 109(12):1818-21. [DOI:10.1016/j.amjcard.2012.02.028] [PMID] [PMCID]
Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010; 21(9):1550-9. [DOI:10.1681/ASN.2009101047] [PMID] [PMCID]
- Abstract Viewed: 65 times
- pdf Downloaded: 6 times